 |
 |
 |
Three Scientists Share
2009 Nobel Prize in Chemistry
The
Royal Swedish Academy of Science has announced the
winners of the 2009 Nobel Prize in Chemistry.
American scientists Venkatraman Ramakrishnan and
Thomas A. Steitz , and Ada E. Yonath of Israel were
bestowed the honor "for studies of the structure and
function of the ribosome." They will share the $1.4
million award.
While
they worked independently, all three published their
breakthrough results in 2000. Through their
extensive research, the scientists showed what the
ribosome looks like and how it functions at the
atomic level. Each of the scientists used X-ray
crystallography to map the atom-by-atom position for
each of the hundreds of thousands of atoms that make
up a ribosome. Because they produce the proteins
which control the chemistry of plants, animals and
humans, ribosomes are crucial to life.
The research has certain significant medical
implications. The three-dimensional models developed
illustrate how different antibiotics bind to
ribosomes. Such knowledge and understanding can
guide scientists in the development of new
antibiotics. Many of those in use today cure
diseases by blocking the function of bacterial
ribosomes. Ribosomes are a vital target for new
antibiotics because the disease-causing bacteria are
unable to function without them.
Founded in 1739 and headquartered in Stockholm, the
Royal Swedish Academy of Sciences is one of the
Royal Academies of Sweden. The academy’s primary
goal is to promote scientific research and defend
the freedom of science. It is an independent,
non-governmental scientific organization that,
through relations with other academies, maintains
international contact and communications among
scientific researchers. Six prizes are awarded
annually with one each in the fields of Physics,
Chemistry, Literature, Economics,
Physiology/Medicine and Peace. Support for the
awards comes from a fund bequeathed for that purpose
by Alfred Nobel, a Swedish industrialist and
inventor.
|
 |
 |
 |
 |
|
|
|
 |
|
|
 |
 |
 |
Air Products Continues to
Expand Asian Market Share
Air Products has signed a long-term contract
to provide nitrogen to NexPower Technology
Corporation (NexPower), at its new thin-film
photovoltaic (PV) facility in the Central
Taiwan Science Park (CTSP) in Houli,
Taichung, Taiwan. The agreement was made
through its subsidiary Air Products San Fu
Co. Ltd. in Taiwan. Nitrogen is being
supplied to the facility through Air
Products’ pipeline network in the CTSP. The
CTSP is one of the two new
government-sponsored science parks in Taiwan
to attract investments and the
development of high-tech industries to the
central Taiwan district. NexPower is one of
the first Taiwan companies to achieve
successful thin-film mass production.
Air Products won over 20 new contracts last
year in Asia, serving both thin-film PV and
crystalline markets. The company has since
signed gas supply contracts with leading PV
manufacturers. Its established service
history in both the semiconductor and
thin-film transistor liquid crystal display
(TFT-LCD) industries makes Air Products well
positioned to serve the thin-film PV
industry.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
KMG Chemicals
Forms Alliance with AgriLabs, Inc.
Global provider of specialty chemicals
KMG Chemicals, Inc. has formed a strategic
partnership in the Animal Health marketplace
with Missouri-based AgriLabs, Inc. The
alliance will provide KMG’s animal
insecticide product line with AgriLabs’
sales, marketing and technical support
necessary to enhance customer service and
increase the exposure for products in the
cattle, swine, dairy and equine markets.
AgriLabs’ technical support team will
provide both customers and producers with
veterinary and animal production expertise
while KMG’s Avenger® and Patriot® ear tags
and quality insecticides will be added to
the AgriLabs product portfolio.
|
 |
|
|
 |
 |
 |
Sigma-Aldrich
Elects New Company Director
Dr. George M. Church has been elected
Director of Sigma-Aldrich Corporation. The
Professor of Genetics at the Harvard Medical
School and Director of the Center for
Computational Genetics in Cambridge,
Massachusetts, Dr. Church has more than 10
U.S. patents granted and several pending. He
pioneered technology innovations in both the
Chemistry and Biomedicine fields. His
background in science and research will help
the company it its efforts to strengthen its
leadership position in the industry.

Executive
Changes Take Place at Air Products
Air Products has announced several executive
changes, effective October 2009.
As an expansion of his current role as Latin
America/South Africa vice president, Michael
A. Olivares has been appointed vice
president, International. His
responsibilities will include growth and
profitability of all international joint
ventures and partnerships of Air Products.
He joined Air Products in 1978 and has held
engineering and operations positions as well
as management roles for Air Products Puerto
Rico and Air Product’s joint venture
company, Bangkok Industrial Gas Ltd. in
Thailand.
Alexander W. Masetti will be responsible for
expanding Air Product’s Six Sigma and Lean
capabilities in his appointment as vice
president, Continuous Improvement. Masetti
joined Air Products in 1981 as an engineer
and has held management positions within the
Process Gas Division. He’s held vice
president positions at Air Product’s joint
venture companies; San Fu Chemical Company
in Taipei, Taiwan and Daido Air Products
Electronics in Osaka, Japan. Masetti’s most
recent vice president position was within
Air Product’s Tonnage Gases North America
Division.
Replacing Masetti as vice president, North
America Tonnage Gases, is Wilbur W. Mok. His
responsibilities will include growing and
directing existing pipeline, franchise, and
on-site offerings. Mok joined Air Products
in 1986 as a financial analyst and held
various domestic and international
engineering, commercial, and management
positions. Mok served as president of Air
Products China before his most recent
position as president of the Asia region.

Innophos Elects
Salmon Vice President and Chief Financial
Officer
Innophos recently announced that Neil Salmon
had been elected Vice President and Chief
Financial Officer by its Board of Directors.
Mr. Salmon will oversee the financial
activities of the Innophos companies,
including accounting and regulatory
reporting requirements, management of
external financial relationships, and
compliance with Sarbanes-Oxley.
Mr. Salmon has held various finance and
accounting positions with Imperial Chemical
Industries P.L.C. for nearly twenty years
most recently serving as ICI’s Adhesives
Business Group’s Chief Financial Officer. He
assumed his responsibilities at the
specialty phosphate producer’s corporate
headquarters in Cranbury, New Jersey the
first week of October.

|
 |
 |
 |
 |
|
|
 |
 |
 |
Lonza Completes
Acquisition of Simbiosys Biowares

Lonza Group has expanded
its cell-biology platform with its
acquisition of Simbiosys Biowares India Pvt.
Ltd. Based in Bangalore, India, Simbiosys
Biowares is a premier biology outsourcing
company with core competencies in molecular
and cell biology and clinical services. The
deal is in sync with Lonza’s strategy to
further develop its life-science platform
and to expand its global cell biology
portfolio. In addition, it strengthens the
company’s position as global leader in cell
discovery by integrating a unique service
model into Lonza’s portfolio.
Simbiosys Biowares India Pvt Ltd offers
preclinical services in the areas of drug
discovery, molecular biology contract
research and biopharmaceuticals
.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
DyStar Files
Insolvency, Stops Production in Germany
Major textile chemical manufacturer, DyStar,
has been forced to stop production at its 5
manufacturing sites in Germany – Frankfurt,
Leverkusen, Brunsbuttel, Gerestried and
Ludwigshafen.
Three temporary insolvency administrators
were appointed by a Frankfurt court after
the company filed insolvency late in
September due to its inability to pay wages
and bills. While DyStar management and the
administrators work to secure financing to
resume production, KPMG consultants have
been hired to find an investor to buy DyStar.
In the meantime, DyStar’s 1,300 workers are
receiving insolvency pay by the employment
office. It is unclear whether the insolvency
had affected DyStar’s production outside
Germany.
DyStar ranks with Clariant and Huntsman as
one of the world’s largest textile chemical
producers.
|
 |
 |
 |
 |
Dow Chemical
Completes Divesture of Morton Salt
Dow Chemical Company recently completed the
sale of its interest in Morton International
Inc. to K+S Aktiengesellschaft for $1.68
billion. The deal for the Morton Salt
business is expected to make the Kassel,
Germany-based company the largest salt
producer in the world.
Dow will use approximately $1billion of the
proceeds from the sale to pay off a bridge
loan used for its acquisition of Rohm and
Haas Co. from earlier in the year. As part
of its broader deleveraging plan, Dow will
use the remaining sale proceeds and those
from future, non-strategic definitive
divestiture agreements to pay down other
debt.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Trimeris
Announces Merger Agreement
Biopharmaceutical
company, Trimeris, Inc. has entered into a
merger agreement with Korean corporation,
Arigene Co., Ltd. Under the agreement,
Arigene will acquire Trimeris for
approximately $81 million through a cash
tender offer of $3.60 per share. A merger
will follow whereby Arigene will obtain all
remaining Trimeris shares at the same price
per share paid in the tender offer. Voting
agreements from Trimeris’ stockholders have
been executed in support of the merger and
the transaction has been approved by the
boards of directors of both companies. The
parties expect the tender offer and merger
to be completed in the fourth quarter of
2009. If successful, Arigene’s wholly owned
subsidiary, RTM Acquisition Company will be
merged with and into Trimeris. Trimeris will
continue as the surviving corporation and as
a result of the merger, will become a
wholly-owned subsidiary of Arigene.
|
|

|
|
Solvay’s
Pharmaceuticals Business Acquired by Abbott
Abbott is to
acquire Solvay Group’s pharmaceuticals
business providing a presence in global
emerging markets. The $6.6 billion
acquisition will provide Abbott with global
right to the fenofibrate franchise. Abbott
currently owns U.S. rights to fenofibrate
and pays royalties to Solvay.
Solvay’s treatments for Parkinson’s disease,
vertigo, irritable bowel syndrome, and
Ménière’s disease as well as exocrine
pancreatic insufficiency and men’s and
women’s hormonal health, will complement
Abbot’s presence in the neuroscience,
gastroenterology, and cardiovascular disease
markets.
The transaction will also include Solvay’s
small molecular diagnostics unit and
vaccines business, which will expand Abbot’s
global vaccines presence.
As a result of this acquisition, Solvay
Pharmaceuticals, based in Belgium, will add
more than $3 billion in annual sales,
primarily outside the U.S. in such markets
as Eastern Europe and Asia. Abbott will
increase its annual pharmaceutical Research
and Development investment by $500 million.
|
 |
|
|
| |
|
CalciTech
Synthetic Minerals Files New Patent
CalciTech Synthetic Minerals Ltd., a
wholly-owned subsidiary of CalciTech Ltd.,
has filed an application for a new patent at
the UK Patent Office. The new patent will
extend the patent protection of CalciTech’s
process and product to be utilized in
production of a Synthetic Calcium Carbonate
("SCC"). Equivalent applications will be
filed in due course claiming the benefit of
the UK filing date to obtain patent coverage
in all major markets.
The SCC possesses a variety of features
including a unique morphology (rice grain
shape), a very narrow particle size
distribution and exceptional purity, which
produces a very high brightness. To satisfy
the large majority of applications, the
company typically produces particles in the
sub-micron range. In this scenario however,
CalciTech can use the identical process for
production of other particle sizes in the
nano and micron range. Such a wide range of
capability opens up additional applications
in expanding markets. The company has
focused considerable time and energy towards
the development of the processes at both
laboratory scale and in the pilot plant.
|
|
|
|
|
|
 |
|
|
|
|
|
Albermarle
Introduces New Cost-Effective Catalyst

Baton Rouge, Louisiana-based specialty
chemical developer Albemarle Corporation has
produced a cost-effective catalyst that
improves both hydroprocessing and
profitability. The company recently
introduced Ketjenfine® 868 (“KF 868”), a
product designed to significantly improve
the performance of vacuum gas oil ("VGO")
hydrocracking pretreatment performance.
Built on Albemarle's patented
STARS™technology, KF 868 offers
best-in-class hydroprocessing activity for
VGO units where both high aromatics
saturation and hydrodenitrogenation activity
are required. It improves VGO hydrocracking
operations by providing step-out performance
and represents the high-end solution for
hydrocracking pretreatment units. It
optimizes catalyst cycle length while
increasing output and enabling refiners to
process cheaper, lower-quality feedstocks
without additional capital expenses.
KF 868 is the latest catalyst development
from Albemarle and is a major asset for the
Hydroprocessing Alliance between the company
and Honeywell’s UOP. A collaboration of
resources between Albermarle and UOP, the
Hydroprocessing Alliance delivers the most
comprehensive portfolio of processes,
catalysts, equipment and services available.
The Alliance offers customized
hydroprocessing solutions designed to
optimize unit performance and improve yields
in refineries worldwide.
|
|
|
|
|
|
 |
|
|
|
|
 |
![]() |
Folotyn™ Granted
Accelerated Approval in U.S.
The FDA granted accelerated approval of
Folotyn™, manufactured by Allos
Therapeutics, Inc. The single agent
treatment is now available for commercial
sale in the United States.
Folotyn™ (pralatrexate injection) is a new
therapeutic option used to treat patients
with relapsed or refractory peripheral
T-cell lymphoma (PTCL). It is the first and
only drug approved by the FDA for this
indication. It is now available to U.S.
health care providers and will be marketed
and sold through Allos’ 25 sales
specialists, which is expected to increase
to approximately 50 sales specialists before
its full-scale launch in January, 2010.
Allos Therapeutics, Inc., headquartered in
Westminster, Colorado, is a
biopharmaceutical company specializing in
the development and commercialization of
anti-cancer therapeutics.
|
 |
 |
 |
 |

|
 |
 |
|
|
|
ISP
Pharmaceuticals Embarks on Drug Solubility
Initiative
Leading global supplier
of specialty chemicals ISP Pharmaceuticals
has launched a Drug Solubility initiative.
The emphasis of the enterprise will be on
R&D in support of those pharmaceutical
companies working with drug actives that
exhibit poor solubility. ISP will expand its
facilities and increase its personnel
dedicated to solubilization efforts and
establish alliances with other companies
involved in developing technologies for
solubilization and outreach programs to the
industry.
By using its expertise in material science
as well as a broad portfolio of ingredients
as the foundation for activities ranging
from traditional formulation technologies to
work with emerging formulation technologies,
ISP will address the solubility issue on
several fronts and opening up numerous
opportunities for pharmaceutical companies.
Companies could realize improved safety and
efficacy, better patient compliance and the
ability to maximize their intellectual
property over a longer period of time. ISP
will develop a database of solutions to
assist pharmaceutical companies develop
workable commercial solutions, with every
drug active having its own range of
requirements and each project having
specific physical and cost parameters.
|
|
|
 |
 |

|
 |
 |
 |
|
|
|
|
|
 |
 |
 |
Novapex Starts
Isopropanol Production
Novapex announced it will start isopropanol
production at its new unit in Roussillon,
France. The phenol and acetone producer will
begin production at its 40,000 tonne/year
unit January 1, 2010. Novapex will use its
own acetone supply as feedstock to produce
isopropanol in three grades to serve
cosmetic, technical, and pharmaceutical
markets. In addition, local contractor ERAS
and Mitsui-licensed technology will allow
the facility to be fully upstream
integrated. Novapex, a Novacap subsidiary,
is the only isopropanol production unit in
Southern Europe. Novacap has been active in
the acids, phenol/acetone, soda ash, and
sodium bicarbonate sectors since 2003.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
|
|
|
|
|
 |
 |
 |
Dia Moulding
Starts Factory in Slovakia
Japanese parent company, Mitsubishi Plastics
has opened its Slovakian plastic moulding
production facility – Dia Moulding Slovakia.
Located in Nitra, Slovakia, the $33.9
million factory will initially produce
moulding parts used in home appliances, and
may also manufacture car parts in the
future. Start-up of the facility will enable
Mitsubishi Plastics to provide the same
goods it supplies to the Japanese market to
those in Europe. Dia Moulding was
established in 2008 to provide production
bases in eastern and central Europe. |
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
 |
 |
 |
Metabolix
Awarded USDA Grant

Bioscience company, Metabolix, Inc. has
received a grant from the U.S. Department of
Agriculture. Awarded by the Department’s
Cooperative State Research, Education and
Extension Service (CSREES), it will fund a
program designed to produce advanced
formulations of bioplastic for use on
commercial scale equipment running at
manufacturing spee. Metabolix will use the
award to further enhance biobased,
biodegradable resins suitable for blow
molding operations.
According to the American Plastics Council,
more than 2 million tons of HDPE plastic
each year is used to produce blow molded
bottles, containers and other products. As
the major components of the traditional
petroleum-based plastics manufacturing
industry, they are suitable for replacement
by biobased, biodegradable materials.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
 |
|
|
 |
|
|
 |
|
|
|
|